Vescor Therapeutics
We are a preclinical company focused on the discovery and development of autophagy targeted therapeutics for cancer treatment.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
N/A | Spinout | ||
| Total Funding | 000k | ||
Related Content
Vescor Therapeutics, LLC is a preclinical biotechnology company dedicated to the discovery and development of autophagy-targeted therapeutics, primarily for cancer treatment. Autophagy is a cellular process that can sustain tumor growth and provide resistance to existing therapies. By inhibiting autophagy, Vescor aims to dramatically impact tumor growth and improve treatment outcomes. The company operates in the oncology market, focusing on developing potent and specific autophagy inhibitors to advance these findings into clinical practice. Vescor serves pharmaceutical companies and healthcare providers looking for innovative cancer treatment solutions. The business model revolves around research and development, with revenue generated through partnerships, grants, and potential future licensing agreements.
Keywords: autophagy, cancer therapeutics, tumor growth, resistance mechanisms, preclinical development, biotechnology, oncology, inhibitors, research, innovation.